Literature DB >> 34120840

The lung microbiome in lung transplantation.

John E McGinniss1, Samantha A Whiteside1, Aurea Simon-Soro2, Joshua M Diamond1, Jason D Christie3, Fredrick D Bushman4, Ronald G Collman5.   

Abstract

Culture-independent study of the lower respiratory tract after lung transplantation has enabled an understanding of the microbiome - that is, the collection of bacteria, fungi, and viruses, and their respective gene complement - in this niche. The lung has unique features as a microbial environment, with balanced entry from the upper respiratory tract, clearance, and local replication. There are many pressures impacting the microbiome after transplantation, including donor allograft factors, recipient host factors such as underlying disease and ongoing exposure to the microbe-rich upper respiratory tract, and transplantation-related immunosuppression, antimicrobials, and postsurgical changes. To date, we understand that the lung microbiome after transplant is dysbiotic; that is, it has higher biomass and altered composition compared to a healthy lung. Emerging data suggest that specific microbiome features may be linked to host responses, both immune and non-immune, and clinical outcomes such as chronic lung allograft dysfunction (CLAD), but many questions remain. The goal of this review is to put into context our burgeoning understanding of the lung microbiome in the postlung transplant patient, the interactions between microbiome and host, the role the microbiome may play in post-transplant complications, and critical outstanding research questions.
Copyright © 2021 International Society for Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  chronic lung allograft dysfunction; hostmicrobe interactions; lung microbiome; lung transplantation

Mesh:

Year:  2021        PMID: 34120840      PMCID: PMC8335643          DOI: 10.1016/j.healun.2021.04.014

Source DB:  PubMed          Journal:  J Heart Lung Transplant        ISSN: 1053-2498            Impact factor:   13.569


  108 in total

1.  Consequences of donor-derived passengers (pathogens, cells, biological molecules and proteins) on clinical outcomes.

Authors:  Gregory Snell; Steven Hiho; Bronwyn Levvey; Lucy Sullivan; Glen Westall
Journal:  J Heart Lung Transplant       Date:  2019-06-20       Impact factor: 10.247

Review 2.  Mechanistic insight into the function of the microbiome in lung diseases.

Authors:  Niki D J Ubags; Benjamin J Marsland
Journal:  Eur Respir J       Date:  2017-09-11       Impact factor: 16.671

3.  Transplanting the pulmonary virome: Dynamics of transient populations.

Authors:  Alicia B Mitchell; Bassel Mourad; Lucy C Morgan; Brian G G Oliver; Allan R Glanville
Journal:  J Heart Lung Transplant       Date:  2018-06-09       Impact factor: 10.247

Review 4.  Lung Transplantation.

Authors:  Vivek N Ahya; Joshua M Diamond
Journal:  Med Clin North Am       Date:  2019-03-13       Impact factor: 5.456

5.  Loss of Microbial Niche Specificity Between the Upper and Lower Airways in Patients With Cystic Fibrosis.

Authors:  Steven D Pletcher; Andrew N Goldberg; Emily K Cope
Journal:  Laryngoscope       Date:  2018-10-03       Impact factor: 3.325

6.  Analysis of the upper respiratory tract microbiotas as the source of the lung and gastric microbiotas in healthy individuals.

Authors:  Christine M Bassis; John R Erb-Downward; Robert P Dickson; Christine M Freeman; Thomas M Schmidt; Vincent B Young; James M Beck; Jeffrey L Curtis; Gary B Huffnagle
Journal:  MBio       Date:  2015-03-03       Impact factor: 7.867

7.  Randomised, double-blind, placebo-controlled trial with azithromycin selects for anti-inflammatory microbial metabolites in the emphysematous lung.

Authors:  Leopoldo N Segal; Jose C Clemente; Benjamin G Wu; William R Wikoff; Zhan Gao; Yonghua Li; Jane P Ko; William N Rom; Martin J Blaser; Michael D Weiden
Journal:  Thorax       Date:  2016-08-02       Impact factor: 9.139

8.  Temporal response of the human virome to immunosuppression and antiviral therapy.

Authors:  Iwijn De Vlaminck; Kiran K Khush; Calvin Strehl; Bitika Kohli; Helen Luikart; Norma F Neff; Jennifer Okamoto; Thomas M Snyder; David N Cornfield; Mark R Nicolls; David Weill; Daniel Bernstein; Hannah A Valantine; Stephen R Quake
Journal:  Cell       Date:  2013-11-21       Impact factor: 41.582

9.  Depletion of Abundant Sequences by Hybridization (DASH): using Cas9 to remove unwanted high-abundance species in sequencing libraries and molecular counting applications.

Authors:  W Gu; E D Crawford; B D O'Donovan; M R Wilson; E D Chow; H Retallack; J L DeRisi
Journal:  Genome Biol       Date:  2016-03-04       Impact factor: 13.583

10.  Comparing microbiotas in the upper aerodigestive and lower respiratory tracts of lambs.

Authors:  Laura Glendinning; David Collie; Steven Wright; Kenny M D Rutherford; Gerry McLachlan
Journal:  Microbiome       Date:  2017-10-27       Impact factor: 14.650

View more
  2 in total

Review 1.  The lung microbiome: progress and promise.

Authors:  Samantha A Whiteside; John E McGinniss; Ronald G Collman
Journal:  J Clin Invest       Date:  2021-08-02       Impact factor: 19.456

Review 2.  The Impact of Human Microbiotas in Hematopoietic Stem Cell and Organ Transplantation.

Authors:  Tirthankar Sen; Rajkumar P Thummer
Journal:  Front Immunol       Date:  2022-07-07       Impact factor: 8.786

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.